Winfield v. Eloxx Pharmaceuticals, Inc.

CourtDistrict Court, D. Delaware
DecidedJanuary 21, 2020
Docket1:19-cv-00447
StatusUnknown

This text of Winfield v. Eloxx Pharmaceuticals, Inc. (Winfield v. Eloxx Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Winfield v. Eloxx Pharmaceuticals, Inc., (D. Del. 2020).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE JOHN WINFIELD, ) ) Plaintiff, ) ) Vv. ) Civil Action No. 19-447-RGA ) ELOXX PHARMACEUTICALS, INC., ) DAVID RECTOR, JAMES SCHMIDT, ) BARRY HONIG, and DOES 1-10, ) inclusive, ) ) Defendants. ) REPORT AND RECOMMENDATION I. INTRODUCTION Presently before the court in this securities action for violations of Sections 10(b) and 20 of the Securities Exchange Act of 1934 (the “Exchange Act”) are the following motions:! (1) the motion to dismiss for failure to state a claim under Rule 12(b)(6), filed by defendants Eloxx Pharmaceuticals, Inc.” (“Eloxx” or “the Company”), David Rector, and James Schmidt (D.I. 8); and (2) the motion to dismiss for failure to state a claim under Rule 12(b)(6), filed by defendant Barry Honig (together with Eloxx, Mr. Rector, and Mr. Schmidt, “Defendants”) (D.I. 11). For the following reasons, I recommend that the court grant-in-part the motion to dismiss filed by Eloxx, Mr. Rector, and Mr. Schmidt, and deny the motion to dismiss filed by Mr. Honig. Il. BACKGROUND Plaintiff John Winfield (“Plaintiff”) is an individual investor who owns 40,000 shares of the Company’s common stock. (D.I. 1 at 9.1) In July 2016, Plaintiff bought 200 shares of Series

' The briefing, declarations, and other filings associated with the pending motions can be found at D.I. 9, D.I. 10, D.I. 12, D.I. 13, D.I. 20, D.I. 21, D.I. 22, and D.I. 23. * Eloxx was formerly known as Sevion Therapeutics, Inc. (D.I. 1 at § 2)

A preferred stock which were convertible into 266,666 shares of common stock. (/d. at § 8) Months later, Plaintiff was contacted by Mr. Rector, the Company’s interim chief executive officer (“CEO”), and Mr. Honig, an independent investor. (/d. at §] 3,5, 13) Mr. Rector and Mr. Honig explained that the Company was low on financing, and it was necessary to convert all Series A preferred shares to common shares before the Company could obtain additional capital. (Ud. at Jf 9, 13) Accordingly, Mr. Rector and Mr. Honig encouraged Plaintiff to enter into an agreement to convert his Series A preferred shares to common shares at a more favorable price. (Id. at § 10) Plaintiff conditioned his agreement to the conversion price on the inclusion of a most-favored-nations provision, which would require the Company to provide notice to Plaintiff of lower conversion rates offered to other investors, and offer those lower conversion rates to Plaintiff. (/d.) On January 18, 2017, Plaintiff executed the Preferred Stock Exchange Agreement (the “Agreement”) with the Company. (D.I. 1 at 11-13) Pursuant to the terms of the Agreement, Plaintiff agreed to exchange his Series A preferred stock for shares of common stock at a $0.25 per share conversion rate, which would amount to 800,000 shares of common stock. (/d. at □□ 10-11) Section 2.2(g) of the Agreement also included a provision promising to notify Plaintiff of any more favorable terms and conditions offered to others and amend the terms of Plaintiff's Agreement to match the more favorable terms and conditions: The Company hereby represents and warrants as of the date hereof and covenants and agrees from and after the date hereof that none of the terms offered to any person with respect to any consent, release, amendment, settlement or waiver relating to the terms, conditions and transactions contemplated hereby (each a “Settlement Document”), is or will be more favorable to such person than those of the Holder and this Agreement. If, and whenever on or after the date hereof, the Company enters into a Settlement Document, then (i) the Company shall provide notice thereof to the Holder immediately following the occurrence thereof and (ii) the terms and conditions of this Agreement shall be, without any further action by

the Holder or the Company, automatically amended and modified in an economically and legally equivalent manner such that the Holder shall receive the benefit of the more favorable terms and/or conditions (as the case may be)... . (Ud. at J 12; D.I. 13, Ex. C at 5) Plaintiff did not immediately convert his preferred shares to common stock after executing the Agreement. (D.I. 1 at J 13) In the weeks after Plaintiff executed the Agreement, Mr. Rector and Mr. Honig pressured Plaintiff to convert his Series A preferred shares to common shares in a series of telephone calls and emails. (/d. at J§ 9, 13-15) Mr. Rector represented that Plaintiff's delay in converting his preferred shares could jeopardize the necessary financing. (/d. at § 14) Mr. Honig indicated that he expected to buy all other unconverted Series A preferred shares, and he promised Plaintiff that he would receive the most favorable conversion price for his Series A preferred shares. (/d. at J 15) Plaintiff refused to convert his shares before receiving confirmation that all other Series A preferred shares had been converted at the same price offered to Plaintiff. (/d. at 13, 15) In filings made with the Securities and Exchange Commission (“SEC”) in May 2017, the Company represented that 110 shares of Series A preferred stock were converted to common stock on February 15, 2017 at an exchange price of $0.25 per share, and 270 shares of Series A preferred stock remained outstanding. (D.I. 1 at § 16) Mr. Honig contacted Plaintiff on May 25, 2017, disclosing that he planned to buy the remaining 70 shares of Series A preferred stock and encouraging Plaintiff to convert his Series A preferred shares at the $0.25 exchange price. (/d. at 49 17-18) In a June 2017 SEC filing, the Company publicly announced that it had agreed to a merger with Eloxx Pharmaceuticals Ltd. on May 31, 2017.7 (D.I. 1 at 919) condition precedent to the completion of the merger, the Company was required to convert all outstanding 3 The merger was ultimately consummated on December 19, 2017. (D.I. 1 at § 31)

Series A preferred stock into common stock. (/d. at f§ 19-20) Mr. Schmidt, the Company’s interim chief financial officer (“CFO”) during the relevant time frame, informed Plaintiff that the holder of the remaining 70 shares of Series A preferred stock had reached an agreement with the Company to tender the shares at a conversion price of $0.25 per share. (/d. at § 21) In or around July 2017, Plaintiff converted his 200 shares of Series A preferred stock into 800,000 shares of common stock at a conversion price of $0.25 per share. (D.I. 1 at 722) The following month, Mr. Honig purchased the 70 outstanding Series A preferred shares and reached his own agreement with the Company to convert those shares to common stock at $0.10 per share. (/d. at J 23-24) Mr. Honig converted the Series A preferred shares to common stock on August 24, 2017 at the $0.10 conversion price to obtain 700,000 shares of common stock. (/d. at 24-25) Plaintiff learned about Mr. Honig’s conversion price from the 2017 Form 10-K filed with the SEC in October 2017. (D.L. 1 at §§ 23-24) The Form 10-K also disclosed that the Company amended its convertible notes to provide noteholders, including OPKO Health, Inc. (““OPKO”) and its CEO, Dr. Phillip Frost, a conversion price of $0.10 on February 15, 2017 and May 22, 2017. Ud. at J§ 27-30) The Company did not notify Plaintiff of its preferred stock exchange agreement with Mr. Honig or its amendment of the convertible notes. (/d. at § 33) On September 7, 2018, the SEC filed a complaint in the Southern District of New York against Dr. Frost, Mr. Honig, OPKO, and several others, alleging that they had orchestrated three “pump-and-dump” schemes from 2013 through 2018.* (D.I. 1 at § 28) Specifically, the SEC

4 The SEC defines “pump-and-dump” schemes as follows: In a pump and dump scheme, fraudsters typically spread false or misleading information to create a buying frenzy tha will “pump” up the price of a stock and

complaint alleged that Mr. Honig, Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Dura Pharmaceuticals, Inc. v. Broudo
544 U.S. 336 (Supreme Court, 2005)
Tellabs, Inc. v. Makor Issues & Rights, Ltd.
551 U.S. 308 (Supreme Court, 2007)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
In Re: Rockefeller Center Properties, Inc. Securities Litigation, Charal Investment Company Inc., a New Jersey Corporation C.W. Sommer & Co., a Texas Partnership, on Behalf of Themselves and All Others Similarly Situated Alan Freed Jerry Crance Helen Scozzanich Sheldon P. Langendorf Rita Walfield Robert Flashman Renee B. Fisher Foundation Inc. Frank Debora Wilson White Stanley Lloyd Kaufman, Jr. Joseph Gross v. David Rockefeller Goldman Sachs Mortgage Co. Goldman Sachs Group Lp Goldman Sachs & Co. Whitehall Street Real Estate Limited Partnership v. Wh Advisors Inc. v. Wh Advisors Lp v. Daniel M. Neidich Peter D. Linneman Richard M. Scarlata Frank Debora Wilson White Stanley Lloyd Kaufman, Jr. Joseph Gross, Charal Investment Company Inc., a New Jersey Corporation C.W. Sommer & Co., a Texas Partnership, on Behalf of Themselves and All Others Similarly Situated Alan Freed Jerry Crance Helen Scozzanich Sheldon P. Langendorf Rita Walfield Robert Flashman Renee B. Fisher Foundation Inc. Frank Debora Wilson White Stanley Lloyd Kaufman, Jr. Joseph Gross v. David Rockefeller Goldman Sachs Mortgage Co. Goldman Sachs Group Lp Goldman Sachs & Co. Whitehall Street Real Estate Limited Partnership v. Wh Advisors Inc. v. Wh Advisors Lp v. Daniel M. Neidich Peter D. Linneman Richard M. Scarlata Charal Investment Company Inc. C.W. Sommer & Co. Renee B. Fisher Foundation Helen Scozzanich Jerry Crance Alan Freed Sheldon P. Langendorf Rita Walfield Robert Flashman
311 F.3d 198 (Third Circuit, 2002)
Barry Belmont v. MB Investment Partners, Inc.
708 F.3d 470 (Third Circuit, 2013)
Institutional Investors Group v. Avaya, Inc.
564 F.3d 242 (Third Circuit, 2009)
Winer Family Trust v. Queen
503 F.3d 319 (Third Circuit, 2007)
Phillips v. County of Allegheny
515 F.3d 224 (Third Circuit, 2008)
Oliver B. Cannon & Son, Inc. v. Fidelity & Casualty Co.
484 F. Supp. 1375 (D. Delaware, 1980)
Airborne Health, Inc. v. Squid Soap, LP
984 A.2d 126 (Court of Chancery of Delaware, 2009)
Dunlap v. State Farm Fire & Casualty Co.
878 A.2d 434 (Supreme Court of Delaware, 2005)
Anderson v. Wachovia Mortgage Corp.
497 F. Supp. 2d 572 (D. Delaware, 2007)
E.I. DuPont De Nemours & Co. v. Pressman
679 A.2d 436 (Supreme Court of Delaware, 1996)
Wal-Mart Stores, Inc. v. AIG Life Insurance
901 A.2d 106 (Supreme Court of Delaware, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
Winfield v. Eloxx Pharmaceuticals, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/winfield-v-eloxx-pharmaceuticals-inc-ded-2020.